SPOTLIGHT: Outsiders should see FDA safety data

Some say that if outside researchers had access to drug safety data, disasters like the Vioxx scandal might have been avoided. At present, however, the FDA doesn't let outsiders see clinical trial data unless forced to do so. This secrecy can only do harm, suggests a new commentary in Health Affairs. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.